Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmion

Full company profile

uuid003ilpr

Namestring
Pharmion
Legal namestring
Bristol-Myers Squibb Company
Websiteurl
pharmion.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Pharmion was a specialty biopharmaceutical company that acquired, developed, and commercialized pharmaceutical products for the treatment of hematology and oncology patients. Founded in 1999 and headquartered in Boulder, Colorado, the company was publicly listed on NASDAQ under the ticker PHRM and maintained a workforce of approximately 251-500 employees. The company's strategic focus on blood disorders and cancer placed it in therapeutic areas characterized by high unmet medical need, targeting patients with serious hematologic and oncologic conditions.

Pharmion operated a prescription pharmaceutical business model, distributing approved and investigational medicines through established channels including pharmaceutical wholesalers, specialty pharmacies, hospitals, and direct contracts with healthcare providers and payers. The company engaged prescribing specialists such as oncologists and hematologists through field sales teams, and negotiated formulary placement and reimbursement with pharmacy benefit managers and insurance providers. Pricing was managed through confidential negotiated contracts with payers rather than public list pricing, consistent with prescription biopharmaceutical industry practice. The company raised $105M in two private financing rounds during 2001-2002 and executed at least one inorganic pipeline addition through the 2006 acquisition of Cabrellis Pharmaceuticals.

The company was acquired by Celgene in 2003, integrating its oncology and hematology assets into Celgene's portfolio. Celgene was subsequently acquired by Bristol-Myers Squibb in 2019 for $74 billion, one of the largest pharmaceutical mergers in history. As a result, Pharmion no longer operates as an independent entity, with its former assets now part of BMS's oncology and hematology franchises.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
hematology therapeutics, oncology pharmaceuticals, cancer drug development, biopharmaceutical products, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Biopharmaceuticals
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pharmion engaged in the acquisition, development, and commercialization of pharmaceutical products for the treatment of hematology and oncology patients. The company operated as a specialty biopharmaceutical company focused on blood disorders and cancer treatments, building its portfolio through targeted acquisitions and in-house development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Hematology and oncology pharmaceutical products
CategoryPharmaceuticals
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty biopharma centered on hematologic malignancies and oncology; mirrors Pharmion's hematology-centric, acquisition-friendly growth model and was acquired by AbbVie in 2015.

TypeDirect peer
Description

Specialty pharma built around acquired/in-licensed products in oncology and hematology-supportive care; the closest functional analog to Pharmion's 'acquire, develop, commercialize' playbook.

3Onyx Pharmaceuticals
TypeDirect peer
Description

Mid-cap oncology-focused biopharma with comparable strategic profile to Pharmion; competed in similar hematology/oncology indications and was ultimately acquired by Amgen in 2013.

4Genta Incorporated
TypeEmerging player
Description

Emerging oncology biopharma working on blood-cancer therapeutics; narrower portfolio than Pharmion but directly comparable in therapeutic-area targeting.

5Millennium Pharmaceuticals (Takeda Oncology)
TypeDirect peer
Description

Oncology/hematology-focused biopharma that, like Pharmion, scaled through acquisition and in-licensing before being absorbed into a larger parent (Takeda, 2008).

6MGI Pharma
TypeDirect peer
Description

Specialty biopharmaceutical company of similar vintage focused on oncology and hematology supportive care; directly comparable to Pharmion's acquisition-and-commercialization model and was itself acquired by Eisai in 2007.

7SuperGen
TypeEmerging player
Description

Smaller specialty oncology/hematology developer with overlapping therapeutic focus on blood cancers and supportive care; a relevant sub-scale peer in the same niche.

TypeBroad incumbent
Description

Direct acquirer of Pharmion in 2003 and a larger specialty biopharma in hematology/oncology; comparable portfolio focus and one of the most relevant transaction comps for Pharmion's strategy.

9Genzyme
TypeBroad incumbent
Description

Established specialty biopharma with a strong hematology/oncology and rare-disease portfolio; comparable commercial model of in-licensing/acquiring niche therapeutics for high-unmet-need populations.

TypeDirect peer
Description

Specialty oncology/hematology developer with a similar niche-drug commercialization profile to Pharmion, overlapping on blood-disorder and cancer therapeutics for small patient populations.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmion

Specialty Biopharmaceuticalspharmion.com

What Pharmion does

Pharmion was a specialty biopharmaceutical company that acquired, developed, and commercialized pharmaceutical products for the treatment of hematology and oncology patients. Founded in 1999 and headquartered in Boulder, Colorado, the company was publicly listed on NASDAQ under the ticker PHRM and maintained a workforce of approximately 251-500 employees. The company's strategic focus on blood disorders and cancer placed it in therapeutic areas characterized by high unmet medical need, targeting patients with serious hematologic and oncologic conditions.

Pharmion operated a prescription pharmaceutical business model, distributing approved and investigational medicines through established channels including pharmaceutical wholesalers, specialty pharmacies, hospitals, and direct contracts with healthcare providers and payers. The company engaged prescribing specialists such as oncologists and hematologists through field sales teams, and negotiated formulary placement and reimbursement with pharmacy benefit managers and insurance providers. Pricing was managed through confidential negotiated contracts with payers rather than public list pricing, consistent with prescription biopharmaceutical industry practice. The company raised $105M in two private financing rounds during 2001-2002 and executed at least one inorganic pipeline addition through the 2006 acquisition of Cabrellis Pharmaceuticals.

The company was acquired by Celgene in 2003, integrating its oncology and hematology assets into Celgene's portfolio. Celgene was subsequently acquired by Bristol-Myers Squibb in 2019 for $74 billion, one of the largest pharmaceutical mergers in history. As a result, Pharmion no longer operates as an independent entity, with its former assets now part of BMS's oncology and hematology franchises.

Pharmion firmographics

Firmographics
Name
Pharmion
Legal name
Bristol-Myers Squibb Company
Website
https://pharmion.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Pharmion industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Hematology therapeutics
  • Oncology pharmaceuticals
  • Cancer drug development
  • Biopharmaceutical products
  • Specialty pharmaceuticals

Where Pharmion is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Markets served

Pharmion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Distribution channels3 records

Marketing channels8 records

Pharmion product offering

Product offering

Core offering

Pharmion engaged in the acquisition, development, and commercialization of pharmaceutical products for the treatment of hematology and oncology patients. The company operated as a specialty biopharmaceutical company focused on blood disorders and cancer treatments, building its portfolio through targeted acquisitions and in-house development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hematology and oncology pharmaceutical products

Companies that use Pharmion

Customer profile

Segments5 records

Ideal customer profiles1 record

Pharmion technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pharmion partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Pharmion competitors and assessment

Company assessment

Direct peers

  • Pharmacyclics: Specialty biopharma centered on hematologic malignancies and oncology; mirrors Pharmion's hematology-centric, acquisition-friendly growth model and was acquired by AbbVie in 2015.
  • Jazz Pharmaceuticals: Specialty pharma built around acquired/in-licensed products in oncology and hematology-supportive care; the closest functional analog to Pharmion's 'acquire, develop, commercialize' playbook.
  • Onyx Pharmaceuticals: Mid-cap oncology-focused biopharma with comparable strategic profile to Pharmion; competed in similar hematology/oncology indications and was ultimately acquired by Amgen in 2013.
  • Millennium Pharmaceuticals (Takeda Oncology): Oncology/hematology-focused biopharma that, like Pharmion, scaled through acquisition and in-licensing before being absorbed into a larger parent (Takeda, 2008).
  • MGI Pharma: Specialty biopharmaceutical company of similar vintage focused on oncology and hematology supportive care; directly comparable to Pharmion's acquisition-and-commercialization model and was itself acquired by Eisai in 2007.
  • Cell Therapeutics (CTI BioPharma): Specialty oncology/hematology developer with a similar niche-drug commercialization profile to Pharmion, overlapping on blood-disorder and cancer therapeutics for small patient populations.

Emerging players

  • Genta Incorporated: Emerging oncology biopharma working on blood-cancer therapeutics; narrower portfolio than Pharmion but directly comparable in therapeutic-area targeting.
  • SuperGen: Smaller specialty oncology/hematology developer with overlapping therapeutic focus on blood cancers and supportive care; a relevant sub-scale peer in the same niche.

Broad incumbents

  • Celgene: Direct acquirer of Pharmion in 2003 and a larger specialty biopharma in hematology/oncology; comparable portfolio focus and one of the most relevant transaction comps for Pharmion's strategy.
  • Genzyme: Established specialty biopharma with a strong hematology/oncology and rare-disease portfolio; comparable commercial model of in-licensing/acquiring niche therapeutics for high-unmet-need populations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Pharmion social profiles

Digital presence

Pharmion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmion leadership team

Management profile

Number of profiles

Pharmion funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmion M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmion

What does Pharmion do?

Pharmion engaged in the acquisition, development, and commercialization of pharmaceutical products for the treatment of hematology and oncology patients. The company operated as a specialty biopharmaceutical company focused on blood disorders and cancer treatments, building its portfolio through targeted acquisitions and in-house development.

Is Pharmion a public or private company?

Pharmion is a public company. It is classified as public and is currently operating.

When was Pharmion founded?

Pharmion was founded in 1987. It employs 1 to 10 people.

Where is Pharmion based?

Pharmion is headquartered in Boulder, United States, in the North America region.

Who are Pharmion's main competitors?

Direct peers on record are Pharmacyclics, Jazz Pharmaceuticals, Onyx Pharmaceuticals, Millennium Pharmaceuticals (Takeda Oncology), MGI Pharma and Cell Therapeutics (CTI BioPharma). Emerging players are Genta Incorporated and SuperGen. Broad incumbents are Celgene and Genzyme.

Does Pharmion have an API?

No public API is recorded for Pharmion.

What industry is Pharmion in?

Pharmion's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals